CIBC Bancorp USA’s Recursion Pharmaceuticals RXRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$210K Buy
50,744
+22,339
+79% +$75.7K ﹤0.01% 1961
2026
Q2
$104K Buy
28,405
+5,320
+23% +$17.7K ﹤0.01% 1851
2026
Q1
$70.9K Buy
+23,085
New +$89.2K ﹤0.01% 1702
2025
Q3
$191K Buy
+39,098
New +$205K ﹤0.01% 1275

Other funds holding RXRX

CIBC Bancorp USA's RXRX Position: Q3 2026 in Review

CIBC Bancorp USA increased its Recursion Pharmaceuticals (RXRX) stake by 79% in Q3 2026, buying an estimated $75.7K and bringing the position to 50,744 shares worth $210K. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

CIBC Bancorp USA first reported a position in RXRX in Q3 2025 and has held it in 4 quarters since. 350 funds tracked by Wall St. Rank hold RXRX as of Q3 2026.

  • CIBC Bancorp USA held 50,744 shares of Recursion Pharmaceuticals worth $210K as of Q3 2026.
  • CIBC Bancorp USA bought 22,339 Recursion Pharmaceuticals shares in Q3 2026, an estimated $75.7K.
  • Recursion Pharmaceuticals made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1961 holding.
  • CIBC Bancorp USA first reported a position in Recursion Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 350 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.